Teva Pharmaceutical Industries Ltd Stock Price Today (NSE: IL&FSTRANS)
Fundamental Score
Teva Pharmaceutical Industries Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Teva Pharmaceutical Industries Ltd share price today is ₹2.67, up +0.00% on NSE/BSE as of 17 February 2026. Teva Pharmaceutical Industries Ltd (IL&FSTRANS) is a Small-cap company in the Civil Construction sector with a market capitalisation of ₹93.05 (Cr). The 52-week high for IL&FSTRANS share price is ₹N/A and the 52-week low is ₹N/A.
Teva Pharmaceutical Industries Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Teva Pharmaceutical Industries Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Teva Pharmaceutical Share Price: A Financial Analysis
A key trend shaping the civil construction industry is the increasing emphasis on sustainable and technologically advanced building practices, demanding companies possess both financial strength and innovative capabilities. This analysis delves into the Teva Pharmaceutical share price, currently at ₹2.67, to understand its financial health within this evolving landscape. Examining the available metrics, particularly the absence of a Price-to-Earnings (PE) ratio and a Return on Capital Employed (ROCE) of -18.13%, offers insights into the company's current position.
The lack of a PE ratio suggests the company might not be currently profitable, preventing a standard valuation comparison. More concerning is the negative ROCE of -18.13%. This indicates that Teva Pharmaceutical is not effectively generating profit from its invested capital. This significantly impacts the company's moat, or competitive advantage, because it reduces its ability to reinvest in growth, innovation, or defend market share. A sustained negative ROCE can signal underlying operational inefficiencies or financial distress.
When considering sector peers, it is useful to see how Teva's management stacks up. For example, how does the leadership quality of Teva Pharmaceutical compare to that of
MBL Infrastructure Ltd? A comparative analysis of management experience, capital allocation decisions, and strategic vision could reveal differentiating factors that influence investor confidence and long-term performance.In summary, a deeper dive is warranted to investigate the reasons behind the negative ROCE and the lack of profitability impacting the PE ratio. Understanding the strategic initiatives implemented to address these issues is crucial for assessing the long-term prospects of Teva Pharmaceutical. This analysis is part of a broader 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing a comprehensive overview of the company's financial standing. Note that this is an observational analysis, and is not intended to provide financial advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Teva Pharmaceutical Industries Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of IL&FSTRANS across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Strong Cash Generation (₹847.07 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (73.22%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
8 factors identified
Suboptimal ROCE (-18.13%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.29%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-1100.85%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-51.00% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-10.02x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.42%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (98.23%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Teva Pharmaceutical Industries Ltd Financial Statements
Comprehensive financial data for Teva Pharmaceutical Industries Ltd including income statement, balance sheet and cash flow
About IL&FSTRANS (Teva Pharmaceutical Industries Ltd)
Teva Pharmaceutical Industries Ltd (IL&FSTRANS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Civil Construction sector with a current market capitalisation of ₹93.05 (Cr). Investors tracking IL&FSTRANS share price can monitor key metrics including P/E ratio, promoter holding of 73.22%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
IL&FSTRANS Share Price: Frequently Asked Questions
What is the current share price of Teva Pharmaceutical Industries Ltd (IL&FSTRANS)?
As of 17 Feb 2026, 10:11 am IST, Teva Pharmaceutical Industries Ltd share price is ₹2.67. The IL&FSTRANS stock has a market capitalisation of ₹93.05 (Cr) on NSE/BSE.
Is IL&FSTRANS share price Overvalued or Undervalued?
IL&FSTRANS share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 18.93x. Based on this relative valuation, the Teva Pharmaceutical Industries Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of IL&FSTRANS share price?
The 52-week high of IL&FSTRANS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Teva Pharmaceutical Industries Ltd share price?
Key factors influencing IL&FSTRANS share price include quarterly earnings growth (Sales Growth: 7.66%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Teva Pharmaceutical Industries Ltd a good stock for long-term investment?
Teva Pharmaceutical Industries Ltd shows a 5-year Profit Growth of N/A% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing in IL&FSTRANS shares.
How does Teva Pharmaceutical Industries Ltd compare with its industry peers?
Teva Pharmaceutical Industries Ltd competes with major peers in the Civil Construction. Investors should compare IL&FSTRANS share price P/E of 0.00x and ROE of N/A% against the industry averages to determine competitive standing.
What is the P/E ratio of IL&FSTRANS and what does it mean?
IL&FSTRANS share price has a P/E ratio of N/Ax compared to the industry average of 18.93x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is IL&FSTRANS performing according to Bull Run's analysis?
IL&FSTRANS has a Bull Run fundamental score of N/A/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does IL&FSTRANS belong to?
IL&FSTRANS operates in the Civil Construction industry. This classification helps understand the competitive landscape and sector-specific trends affecting Teva Pharmaceutical Industries Ltd share price.
What is Return on Equity (ROE) and why is it important for IL&FSTRANS?
IL&FSTRANS has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Teva Pharmaceutical Industries Ltd generates profits from shareholders capital.
How is IL&FSTRANS debt-to-equity ratio and what does it indicate?
IL&FSTRANS has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk.
What is IL&FSTRANS dividend yield and is it a good dividend stock?
IL&FSTRANS offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Teva Pharmaceutical Industries Ltd shares.
How has IL&FSTRANS share price grown over the past 5 years?
IL&FSTRANS has achieved 5-year growth rates of: Sales Growth -51.00%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in IL&FSTRANS and why does it matter?
Promoters hold 73.22% of IL&FSTRANS shares, with 98.23% pledged. High promoter holding often indicates strong management confidence in Teva Pharmaceutical Industries Ltd.
What is IL&FSTRANS market capitalisation category?
IL&FSTRANS has a market capitalisation of ₹93 crores, placing it in the Small-cap category.
How volatile is IL&FSTRANS stock?
IL&FSTRANS has a beta of N/A. A beta > 1 suggests the Teva Pharmaceutical Industries Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is IL&FSTRANS operating profit margin trend?
IL&FSTRANS has a 5-year average Operating Profit Margin (OPM) of 2.29%, indicating the company's operational efficiency.
How is IL&FSTRANS quarterly performance?
Recent quarterly performance shows Teva Pharmaceutical Industries Ltd YoY Sales Growth of 7.66% and YoY Profit Growth of -1100.85%.
What is the institutional holding pattern in IL&FSTRANS?
IL&FSTRANS has FII holding of 0.00% and DII holding of 0.42%. Significant institutional holding often suggests professional confidence in the Teva Pharmaceutical Industries Ltd stock.